The Certara Blog

Author: Mark Lovern

Dr. Mark Lovern recently joined Quantitative Solutions with 14 years of experience in applying modeling and simulation tools and techniques toward optimally informing drug development decision-making. Mark’s previous work history has been split approximately equally between biopharmaceutical companies (GSK and UCB) and companies that support the biopharmaceutical industry (Quintiles and Pharsight). In addition to modeling pharmacokinetic and pharmacodynamic data across a wide variety of compounds and therapeutic areas, Mark has also taught over 50 technical training workshops on modeling tools and methodology. His most recent therapeutic area experience has been with therapies for infectious disease and autoimmune disorders. Mark was awarded a Ph.D. in Biomathematics from the North Carolina State University in 1997. His favorite leisure activities include hosting dinner parties, traveling, reading, and enjoying films.

Recent Posts

A Beginner’s Guide to Performing Clinical Trial Simulation

The astronomical cost of conducting clinical drug trials means that a suboptimal trial design adds significant risk to a drug program. Clinical trial simulation allows drug developers to test different trial designs in silico before exposing patients to an experimental drug. In this blog post, I’ll explain how Certara’s Trial Simulator balances ease-of-use with robust […]

Read More
That’s So Meta - How Model-based Meta-analysis Informs Drug Development

That’s So Meta: How Model-based Meta-analysis Informs Drug Development

Making the right choices in drug development often means the difference between getting a new medication to patients and it ending up in the scrap heap of failed programs. There is a surfeit of publically available information on approved drugs as well as those currently in development. How can sponsors turn clinical trial data into […]

Read More